Ivasyk, Iryna
Chatterjee, Abhinaba
Jordan, Catherine
Geiselmann, Matthew T.
Chang, Peter S.
Kamel, Hooman
Khormaee, Sariah
Article History
Received: 22 January 2022
Accepted: 2 June 2022
First Online: 8 July 2022
Declarations
:
: This study was conducted and reported in accordance with the Declaration of Helsinki. The institutional review board and ethical committee at Weill Cornell Medicine gave approval to conduct this study with a waiver of informed consent due to the deidentified nature of the data source.
: Not applicable.
: Ms. Ivasyk has no disclosures, Mr. Chatterjee has no disclosures, Ms. Jordan has no disclosures, Mr. Geiselmann has no disclosures, Dr. Chang has no disclosures, Dr. Kamel serves as a PI for the NIH-funded ARCADIA trial (NINDS U01NS095869) which receives in-kind study drug from the BMS-Pfizer Alliance for Eliquis® and ancillary study support from Roche Diagnostics, serves as Deputy Editor for JAMA Neurology, serves as a steering committee member of Medtronic’s Stroke AF trial (uncompensated), and serves on an endpoint adjudication committee for a trial of empagliflozin for Boehringer-Ingelheim, Dr. Khormaee has no disclosures.